<SEC-DOCUMENT>0001006837-17-000019.txt : 20170302
<SEC-HEADER>0001006837-17-000019.hdr.sgml : 20170302
<ACCEPTANCE-DATETIME>20170302083924
ACCESSION NUMBER:		0001006837-17-000019
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170302
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170302
DATE AS OF CHANGE:		20170302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HC2 HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001006837
		STANDARD INDUSTRIAL CLASSIFICATION:	FABRICATED STRUCTURAL METAL PRODUCTS [3440]
		IRS NUMBER:				541708481
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35210
		FILM NUMBER:		17657042

	BUSINESS ADDRESS:	
		STREET 1:		450 PARK AVENUE
		STREET 2:		30TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		212-235-2690

	MAIL ADDRESS:	
		STREET 1:		450 PARK AVENUE
		STREET 2:		30TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HC2 Holdings, Inc.
		DATE OF NAME CHANGE:	20140415

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTGi HOLDING, INC.
		DATE OF NAME CHANGE:	20131108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIMUS TELECOMMUNICATIONS GROUP INC
		DATE OF NAME CHANGE:	19960814
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8-kremedibeaconpressrelea.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7d2f064bcace40e89235a5b592e3e571"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C.  20549</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:15pt;"><font style="font-family:inherit;font-size:15pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Date of Report (Date of earliest event reported): March 2, 2017</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">HC2 HOLDINGS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.2421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:13%;"></td><td style="width:20%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:20%;"></td><td style="width:13%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-35210</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">54-1708481</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of incorporation)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">450 Park Avenue, 30th Floor</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">New York, NY</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(212) 235-2690</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s telephone number, including area code)</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Not Applicable</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Former name or former address, if changed since last report.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 8.01. Other Events</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On March 2, 2017, HC2 Holdings, Inc. issued a press release entitled "HC2 Portfolio Company MEDIBEACON</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;Inc. Completes Successful Clinical Study of Groundbreaking Kidney Function Monitor", a copy of which is attached as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit 99.1</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 9.01.  Financial Statements and Exhibits</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)  Exhibits</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item No.&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;Description</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">99.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Press Release dated March 2, 2017, entitled "HC2 Portfolio Company MEDIBEACON</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:11pt;">&#160;Inc. Completes Successful Clinical Study of Groundbreaking Kidney Function Monitor"</font></div><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:174%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:174%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: March 2, 2017</font></div><div style="line-height:120%;text-align:center;text-indent:312px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:50.5859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">HC2 Holdings, Inc.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Registrant)</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Paul L. Robinson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  Paul L. Robinson</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:  Chief Legal Officer and Corporate Secretary</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit Index</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item No.&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;Description</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">99.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Press Release dated March 2, 2017, entitled "HC2 Portfolio Company MEDIBEACON</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:11pt;">&#160;Inc. Completes Successful Clinical Study of Groundbreaking Kidney Function Monitor"</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh991-medibeaconpressrele.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s06d23e1768c64c8e805a1e02ec335182"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;"><img src="hc2logoa05.jpg" alt="hc2logoa05.jpg" style="height:105px;width:106px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">HC2 Portfolio Company MEDIBEACON</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;Inc. Completes Successful Clinical Study </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">of Groundbreaking Kidney Function Monitor  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;font-weight:bold;">New York, MARCH 2, 2017 (GlobeNewswire) -</font><font style="font-family:inherit;font-size:10pt;color:#373737;">&#32;HC2 Holdings, Inc. (&#8220;HC2&#8221;) (NYSE MKT: HCHC), a diversified holding company, announced today that </font><font style="font-family:inherit;font-size:10pt;color:#0563c1;text-decoration:underline;">MediBeacon Inc</font><font style="font-family:inherit;font-size:10pt;color:#373737;">., a portfolio company within HC2&#8217;s Pansend Life Sciences subsidiary, successfully completed a real-time, point of care renal function clinical study on subjects with impaired kidney function at Washington University in St. Louis.  During the Pilot Two study, kidney function was measured in subjects ranging from normal to impaired Stage 4 Chronic Kidney Disease (CKD).  The study also included subjects at St. Louis University Hospital.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">&#8220;We are extremely excited by the continued progress MediBeacon has made in validating their technology,&#8221; said Phil Falcone, HC2&#8217;s Chairman, Chief Executive Officer and President.  &#8220;This is a significant milestone that further reinforces our confidence in our investment in MediBeacon and its ability to use innovative technology to improve patient care and reduce costs to the healthcare system.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">MediBeacon&#8217;s proposed Transdermal Glomerular Filtration Rate (&#8220;GFR&#8221;) Monitor uses an optical skin sensor combined with a proprietary fluorescent tracer agent that glows in the presence of light.  The system has been designed to provide clinicians continuous real-time monitoring of kidney function with no need for blood sampling.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">&#8220;Completion of our Pilot Two study on patients with impaired kidney function represents an important milestone,&#8221; said Steve Hanley, MediBeacon CEO.  &#8220;We anticipate beginning our multicenter clinical study including sites in the United States and Europe during the fourth quarter 2017.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">Blood samples taken in clinical practice today provide only time-delayed estimates and suffer from variability that may lead to inaccuracies.  &#8220;Methods to assess kidney function have not changed in 25 years,&#8221; said Dr. Richard Solomon,&#160;Patrick Professor of Medicine and&#160;Director, Division of Nephrology and Hypertension at The University of Vermont College of Medicine.  &#8220;MediBeacon&#8217;s point of care system could represent a major breakthrough in measuring kidney function.&#8221; </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;font-weight:bold;">Other Recent Developments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">Current MediBeacon technology applications are being investigated in the fields of kidney health, gastrointestinal permeability and optical angiography.  The company&#8217;s Intellectual Property (IP) portfolio has grown to 29 granted U.S. patents, with 17 pending patent applications.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">In September 2016, MediBeacon was awarded a grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH) under Award Number R43EY027207.  With this support, the company is pursuing research into the use of a MediBeacon fluorescent tracer agent to visualize vasculature in the eye.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">In October 2016, MediBeacon, in collaboration with Washington University, was awarded a $1.1 million grant from the Bill &amp; Melinda Gates Foundation for a research project aimed at improving the understanding of childhood malnutrition and its related problems, including stunted growth. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;font-weight:bold;">About HC2</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">HC2 Holdings, Inc. is a publicly traded (NYSE MKT:HCHC) diversified holding company, which seeks opportunities to acquire and grow businesses that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders. HC2 has a diverse array of operating subsidiaries across seven reportable segments, including Manufacturing, Marine Services, Utilities, Telecommunications, Life Sciences, Insurance and Other. HC2's largest operating subsidiaries include DBM Global Inc., a family of companies providing fully integrated structural and steel construction services, and Global Marine Systems Limited, a leading provider of engineering and underwater services on submarine cables. Founded in 1994, HC2 is headquartered in New York, New York.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">Learn more about HC2 and its portfolio companies at </font><font style="font-family:inherit;font-size:10pt;color:#0563c1;text-decoration:underline;">www.hc2.com</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;font-weight:bold;">About MediBeacon Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">MediBeacon&#8217;s mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property estate. MediBeacon&#8217;s portfolio includes a renal function system that uses an optical skin sensor combined with a proprietary fluorescent tracer agent that glows in the presence of light. This system, currently in human trials, provides clinicians continuous real-time monitoring of a patient&#8217;s kidney function. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">Learn more about MediBeacon at </font><font style="font-family:inherit;font-size:10pt;color:#0563c1;text-decoration:underline;">www.medibeacon.com</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;font-weight:bold;">Cautionary Statement Regarding Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release contains, and certain oral statements made by our representatives from time to time may contain, forward-looking statements, including statements regarding the commencement or completion of the offering. Generally, forward-looking statements include information describing the offering and other actions, events, results, strategies and expectations and are generally identifiable by use of the words &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; or &#8220;continues&#8221; or similar expressions. The forward-looking statements in this press release include, without limitation, statements regarding our expectation regarding building shareholder value.  Such statements are based on the beliefs and assumptions of HC2&#8217;s management and the management of HC2&#8217;s subsidiaries and portfolio companies. The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance or results, and the Company&#8217;s actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent reports on Forms 10-K, 10-Q and 8-K. Such important factors include, without limitation, the ability of our subsidiaries (including, target businesses following their acquisition) to generate sufficient net income and cash flows to make upstream cash distributions, capital market conditions, our and our subsidiaries&#8217; ability to identify any suitable future acquisition opportunities, efficiencies/cost avoidance, cost savings, income and margins, growth, economies of scale, combined operations, future economic performance, conditions to, and the timetable for, completing the integration of financial reporting of acquired or target businesses with HC2 or the applicable subsidiary of HC2, completing future acquisitions and dispositions, litigation, potential and contingent liabilities, management&#8217;s plans, changes in regulations and taxes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">These risks and other important factors discussed under the caption &#8220;Risk Factors&#8221; in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to HC2 or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and HC2 undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">For information on HC2 Holdings, Inc., please contact:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">Andrew G. Backman</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">Managing Director</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">Investor Relations &amp; Public Relations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0563c1;text-decoration:underline;">abackman@hc2.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#373737;">212-339-5836</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>hc2logoa05.jpg
<TEXT>
begin 644 hc2logoa05.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $] 4(# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_!4;XX_\%.OC?)X\\?3R:3X4TJ1XO!W@VWN&:WTV G_6/SB2X<8WR8_V5PH
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M#<O">-ZC+0LP5L@H[!+1]NT49HH)"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O,/VOOVO_@9^P]\#=6^/WQ_\6QZ9H^FQ$6]NK*;G4;@
M@E+6WC)'F3.1@*. ,L2%!(/VOOVOO@9^P[\#=5^/_P"T!XLCTO1=-79!"OS7
M&H7)!,=K;Q]9)7(.!T !9B%4D?RV?\%._P#@I]\=?^"F_P <)/B)\1KJ32_#
M.FR/'X/\%V]R6M=)@. 6[>9.^ 7E(R3P,*%4 TKCO^"G_P#P4]^.'_!3?XZ2
M_$3XA7$FF^%]+EEB\%^#X9MT&DVS'JQ 'FSN "\I&2>!A0JCYGHHH+"BBB@
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M54WUD&8LT)+*&4DM$QP<@J[!+1]OT444$A1110 4444 %%%% !1110 4444
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MQ_8D_P"C:?"__@$?\:/^(A93_P ^I_='_P"2#_6;!_R2_#_,_"VBOW$\1_\
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MV.&I_P#I5)7]I%?Q;_M"_P#)??''_8X:G_Z524%1./KZJ_X(A?\ *6'X&_\
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M /0M(K\2J"X['[T?L3?\F>?"[_L0=)_])(Z]0KR_]B;_ ),\^%W_ &(.D_\
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M4M_X*5_'7_@IC\=YOBI\5+UK'0]/:2'P=X1MY=UMHMJQ&5' \R5]JM)*1EB
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MW#(W#'AE(KZ]HH **** /P\_X/(?^0E^SO\ ]</%?_H6D5^)5?MK_P 'D/\
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M*^JO^"(7_*6'X&_]CHG_ *(EH*Y3^LZBBB@D_#S_ (/(?^0E^SO_ -</%?\
MZ%I%?B57[:_\'D/_ "$OV=_^N'BO_P!"TBOQ*H+CL?O1^Q-_R9Y\+O\ L0=)
M_P#22.O4*\O_ &)O^3//A=_V(.D_^DD=>H5_-N._WZK_ (I?FS\NQ'^\3]7^
M9X[_ ,% _P#DRGXF?]BG=?\ H-?A37[K?\% _P#DRGXF?]BG=?\ H-?A37ZI
MX>_\BNK_ (__ &V)]=PS_ND_\7Z(****^^/I HHHH *Z+X165KJ7Q8\+Z=?0
M++!<>(K*.:-NCJTZ @^Q!KG:Z;X*?\EE\(_]C-8?^E"4 ?VG6MK;V5O':6L2
MQQPQA(T7HJ@8 J2BB@S"BOE__@KK_P %#D_X)H?L>ZC\?=/\(C7-=OM1CT7P
MO8S.5MQJ$T<KI+.1SY2+$[E1@OM"@KNW#\*I/^#G#_@K6\C.OQ:\-+N;.U?!
MEI@>PRM ['].M%?S$_\ $3=_P5L_Z*]X;_\ ",L__B:/^(F[_@K9_P!%>\-_
M^$99_P#Q- ^5G].=Q<06D#7-U,L<<:EI))&"JJCJ23T K\$O^"^G_!?*7XOS
M:Q^Q+^Q-XO*^$T+V?CGQQI\H_P")TP+*]E:2*3_HO3?*"#*<JO[O)D^/?VC_
M /@O1_P4Z_:B^%FH?!KXB_'M;/0=6C\K5H?#FCP:?+=P]X7FB42>6W1E5@&!
M*ME20?C^PL+[5;Z'3-,LIKFYN9EBM[>WC+R2R,<*BJ.68D@ #DF@%$2RLKW4
MKR'3M.M);BXN)5CM[>&,L\CL<*JJ.223@ <DU_01_P $&/\ @@E8?LTV6E_M
MC?MF^%8;GXAW$8N/"OA&^B62/PU&P!2XE'(:\(Z#I"/]O.U__!!3_@@I8_LT
M6&E_MD_MC>&(KGXB7,*W/A/PK>*'C\-1NO$TRD8:](/':'M\^2OZT8]10#8
M '(HHHH)"BBB@ HHHH Y;XS_  7^%_[0GPNUCX,_&?P99>(/#6O6AMM4TJ_C
MW1RH3D'U5E8!E92&5@""" :_F,_X+(_\$;/BA_P3)^)C>)_#27GB#X3Z]>%?
M#?BAH<M92-N86%WC[LJJ#M?A95&1@AE7^IRN7^,WP9^&/[07PQUCX.?&+P98
MZ_X;UZS:VU/2]0A#QR(>X[JZG#*XPRL P((!H _BOHK[>_X+*?\ !&OXF_\
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MQC^#GPQ^/_PSUCX/?&3P79>(/#>O6C6VJ:3J$>Z.9#S]58$!E92&5@""" :
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M6Y4K1ZOM_FSR/]O[XS^#OV@?VN?&'Q4^'\TDNCWUQ;PV%Q(A7ST@M8K?S0"
M0K&(L 0#@C/-<%\%/^2R^$?^QFL/_2A*YFM_X4ZG8:)\4?#>LZK<K#:VFOV<
MUQ,_W8XUG1F8^P )K]WPV'IX7#PHPVBDEZ)61^A4J<:-.-..R22^6A_:S17)
MZ'\=O@KXDTBU\0:#\7?#%Y8WUNL]I=6VO6[QRQL,JRL'P015S_A;7PJ_Z*9X
M?_\ !U!_\76P'045S_\ PMKX5?\ 13/#_P#X.H/_ (NG0?%+X97<Z6MI\1=!
MEED8+'''J\+,[$X  #<DF@#>HH!)'(HH **** "BBB@ HHHH **** "BBB@
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M(T49+,S$  <DG% !I&D:MX@U6VT+0=+N+Z^O)U@L[.SA:26>5CA41%!+,20
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M#7\S7_!:?_@BM\0_^":WQ!D^)/PXM[W7O@_KE\1H^M>6TDFB2NQVV%XV.O\
MSSE/$@X.'!!_J%KG_BC\+OAY\:?A]JWPK^*W@^QU[P[KEF]KJNDZE )(;B)A
MRI!_,$8((!!! - '\4]%?>G_  6H_P""*OQ"_P"":OC]_B3\-X+[7O@]KE[L
MT?6I%WS:-,W(L;LC\1',<"0#!PX(/PIHVC:QXBU:UT#P_I5S?7U[<)!9V5G
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H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
